News

Pharmaceutical companies need to replenish their portfolios. But are biologics the way to go? Part 2 of Nuala Moran's report from Düsseldorf.

The German Research Foundation is calling for the urgent revision of the country’s 2002 Stem Cell Act.

Just four out of ten Portuguese firms were actively investing in innovation between 2002 and 2004, according to a new report.

The innovation winners will have to use a more disciplined – and science-based – approach to garnering new ideas, says a leading consultant.

Booz Allen Hamilton’s second annual global innovation survey promises to continue last year's debate on the link between R&D spending and corporate performance.